

Amendments to the Claims

1. (Amended) A composition comprising:
 - (a) an admixture comprising a cancer, viral or parasitic antigen expressed by said cancer, virally or parasitic infected cells and a microfluidized antigen formulation, said antigen formulation comprising:
 - (i) a stabilizing detergent,
 - (ii) a micelle-forming agent, and
 - (iii) a biodegradable and biocompatible oil,said antigen formulation being formulated as a stable oil-in-water emulsion and having an ability to induce a cytotoxic T lymphocyte response; and
 - (b) at least one agent which is capable of neutralizing or down regulating the activity of immunosuppressive factors, wherein said composition is capable of inducing a cytotoxic T lymphocyte response that is enhanced relative to a cytotoxic lymphocyte response induced by said antigen formulation.
2. (Original) The composition of Claim 1, wherein said antigen formulation consists essentially of said stabilizing detergent, micelle-forming agent, and biocompatible oil.
3. (Original) The composition of Claim 1, wherein the detergent is selected from the group consisting of TWEEN 80, TWEEN 20, TWEEN 40, TWEEN 60, Zwittergent 3-12, TEEPOL HB7 and SPAN 85.
4. (Original) The composition of Claim 1, wherein said detergent is provided in an amount ranging from approximately 0.05 to 0.5%.
5. (Original) The composition of Claim 4, wherein the amount of detergent is about 0.2%.
6. (Original) The composition of Claim 1, wherein said micelle-forming agent has a hydrophile-lipophile balance of between 0 and 2.

7. (Original) The composition of Claim 6, wherein the amount of said micelle-forming agent ranges from between 1.25 and 5%.

8. (Original) The composition of Claim 1, wherein said micelle-forming agent is selected from the group consisting of poloxamer 401, PLURONIC L62Lf, PLURONIC L101, PLURONIC L64, PEG1000, TETRONIC 1501, TETRONIC 150R1, TETRONIC 701, TETRONIC 901, TETRONIC 1301 and TETRONIC 130R1.

9. (Original) The composition of Claim 1, wherein the amount of said micelle-forming agent ranges from 0.5 to 10%.

10. (Original) The composition of Claim 1, wherein the oil exhibits an melting temperature of less than 65°C.

11. (Original) The composition of Claim 1, wherein the oil is selected from the group consisting of squalane, eicosane, tetratetracontane, pristane, and vegetable oils.

12. (Original) The composition of Claim 1, wherein the amount of oil ranges from between 1 and 10%.

13. (Original) The composition pf Claim 12, wherein the amount of oil ranges from between 2.5 and 5%.

14. (Withdrawn).

15. (Withdrawn).

16. (Original) The composition of Claim 1, wherein the detergent if selected from the group consisting of TWEEN 20, TWEEN 40, and TWEEN 80, the oil is selected from the group consisting of squalane, eicosane, olive oil and pristane and the micelle-forming agent is selected from the group consisting of poloxamer 401, and PLUTRONIC L62Lf.

17. (Amended) The composition of Claim 1, wherein said immunosuppressive ~~factors~~ factor is TGF β .

18. (Original) The composition of Claim 1, wherein said agent which is capable of neutralizing or down regulating the activity of tumor and host secreted immunosuppressive factors is an anti- TGF β antibody, a TGF β R-fusion protein, a TGF β analog, a TGF β binding protein or a TGF β R blocking antibody.

19. (Withdrawn).

20. (Original) The composition of Claim 1, wherein said antigen formulation comprises squalane, TWEEN 80 and poloxamer 401.

21. (Original) The composition of Claim 1, wherein said antigen is selected from the group consisting of gp100, MART-1/Melan A, gp75, tyrosinase, melanoma proteoglycan, MAGE, BAGE, GAGE, RAGE, N-acetylglucosaminyltransferase-V, mutated B-catenin, mutated MUM-1, mutated cyclin dependent kinases-4, p21 ras, BCR-abl, p53, p185 HER2/neu, mutated epidermal growth factor receptor, carcinoembryonic antigens, carcinoma associated mutated mucins, EBNA gene products, papillomavirus E7 protein, papillomavirus E6 protein, prostate specific antigens, prostate specific membrane antigen, PCTA-1, immunoglobulin idiotypes and T cell receptor idiotypes.

22. (Original) The composition of Claim 1, wherein said composition is useful for treating cancer, viral or parasitic disorders.

37. (Amended) A composition comprising:

(a) an admixture comprising a cancer, viral or parasitic antigen expressed by said cancer, virally or parasitic infected cells and a microfluidized antigen formulation, said antigen formulation comprising:

- (i) a stabilizing detergent,
- (ii) a micelle-forming agent, and

(iii) a biodegradable and biocompatible oil,
said antigen formulation being formulated as a stable oil-in-water emulsion and having an ability to induce a cytotoxic T lymphocyte response; and

(b) one or more TGF β antagonists, wherein said composition is capable of inducing a cytotoxic T lymphocyte response that is enhanced relative to a cytotoxic lymphocyte response induced by said antigen formulation.